A cell-permeable quinazoline compound that acts as a potent and reversible CXCR4 antagonist (IC50=36.2nM for SDF-1/CXCL12 binding to hCXCR4-transfected HEK293 membrane) with selectivity over closely related human chemokine receptors CXCR2, CCR2, CCR4 and CCR5 (IC50 >10uM). Shown to inhibit CXCL12-induced Ca2+-mobilization and cell migration in hCXCR4-HEK293 cells (IC50=100.1 and 41nM, respectively), and rapidly mobilize CXCR4+, CD34+ and CD133+ stem cells from bone marrow in C57BL/6 male mice (6mg/kg, s.c).
Synonyms:N²-(4-((3-(Cyclohexylamino)propylamino)methyl)benzyl)-N⁴-(piperidin-4-yl) quinazoline-2,4-diamine, 2HCl, Fusin Antagonist III
Formula:C₃₀H₄₃N₇•2HCl
Molecular Weight:574.6
Solubility:DMSO (50mg/ml)
Purity:≥98% (HPLC)
Appearance:White solid
Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile buffer or dH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Important Note:This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Toxicity and Hazards: All products should be handled by qualified personnel only, trained in laboratory procedures.
